TCR stimulation by agonistic mAb in vivo administration inhibits mouse T-ALL development. TCR stimulation by agonistic mAb in vivo administration inhibits.

Slides:

Advertisements

Similar presentations

c-Myc expression in response to pre-TCR stimulation.

Advertisements

Anti-CD40 and CpG induce activation of T cells in draining lymph nodes

IL-1β significantly augments the angiogenic activity of NSCLC by inducing the expression of angiogenic CXC chemokine genes. IL-1β significantly augments.

Platelet depletion by anti-CD41 (αIIb) mAb injection early but not late in the course of disease protects against Plasmodium berghei pathogenesis by altering.

Morphological analyses of peripheral blood and bone marrow cells isolated from leukemic mice. Morphological analyses of peripheral blood and bone marrow.

Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy by Mark P. Chao, Chad Tang, Russell K. Pachynski,

Effects of senescent cells on activity.

by Jamie Honeychurch, Alison L. Tutt, Thomas Valerius, Ingmar A. F. M

Effects of AG-221 treatment on survival and cell differentiation in an IDH2R140Q primary human AML xenograft model. Effects of AG-221 treatment on survival.

Platelet Toll-like receptor expression modulates lipopolysaccharide-induced thrombocytopenia and tumor necrosis factor-α production in vivo by Rukhsana.

Use of EAS to define TCR-Vb3- and TCR-Cb1-expressing T cells

Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. Combined A2A receptor and PD-1 blockade is not effective in IFNγ−/− mice. AT-3ovadim.

ALT-803 administration increases peripheral blood cell counts of lymphocyte subsets in cynomolgus monkeys. ALT-803 administration increases peripheral.

Fig. 3 In situ vaccination with CpG and anti-OX40 is therapeutic in a spontaneous tumor model. In situ vaccination with CpG and anti-OX40 is therapeutic.

Antitumor effect of local cancer immunotherapy treatment toward distant B16F10 tumors. Antitumor effect of local cancer immunotherapy treatment toward.

Persistence of CAR4 cells is reduced after sustained TCR engagement

Host Basophils Are Dispensable for Induction of Donor T Helper 2 Cell Differentiation and Severity of Experimental Graft-versus-Host Disease Isao Tawara,

Rapamycin inhibits TCR/CD3 engagement-dependent HIF-1α protein expression. Rapamycin inhibits TCR/CD3 engagement-dependent HIF-1α protein expression. Human.

Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in xenografted mice. Anti-CD20 CAR exPBNK significantly inhibit growth of Raji cells in.

Anti-CD96 combines with anti–CTLA-4 or anti–PD-1 to suppress experimental and spontaneous lung metastases. Anti-CD96 combines with anti–CTLA-4 or anti–PD-1.

CD8+ T cells were immunomodulated and required for the efficacy of anti–4-1BB/anti–PD-1 combination treatment. CD8+ T cells were immunomodulated and required.

Genetic FIP200 deletion impairs autophagy induction and causes T cell apoptosis. Genetic FIP200 deletion impairs autophagy induction and causes T cell.

Figure 1 Peripheral blood lymphocyte counts during dose titrationB-lymphocyte (CD19+; A) and total lymphocyte (CD45+; B) counts (cells/µL) in peripheral.

In vivo growth inhibition elicited by afatinib and GSK in a CLU–NRG1-rearranged PDX mouse model. In vivo growth inhibition elicited by afatinib.

Interactions of neutrophil-derived OSM with gp130-containing receptors on endothelial cells enhance P-selectin–dependent rolling in mouse postcapillary.

by Pamela J. Sung, Mayumi Sugita, Holly Koblish, Alexander E

T1D is reduced in anti-CD3–treated, CXCL10-deficient RIP-LCMV-GP mice (the numbers in parentheses indicate the number of mice in each group). T1D is reduced.

Comparison of the percentages of ducts in the pancreas containing cells showing positive staining for the different markers between control hamster Ig–and.

Dox administration was required for Tet-CD19CAR T cells to show a suppressive function against a CD19+ tumor in vivo. Dox administration was required for.

TH-302 has antileukemia activity in an in vivo primary AML xenograft murine model. TH-302 has antileukemia activity in an in vivo primary AML xenograft.

CD8 T cells play a critical role in responses of TILs due to BRAF inhibition. CD8 T cells play a critical role in responses of TILs due to BRAF inhibition.

coTCRcys-transduced T cells control tumor growth in vivo.

PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant p53 in vivo. PRIMA-1Met inhibits the growth of multiple myeloma tumors with mutant.

Anti-Flk-1 treatment inhibits growth of s. c. 4T1 and B16 tumors. s. c

CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated with a longer survival. CD8, galectin-3, galectin-9, and the M1/M2 ratio are associated.

5FU-induced specific activation of CD8+ T cells.

STINGa enhances mAb immunotherapy in BCL1 lymphoma in an FcγR-dependent manner. STINGa enhances mAb immunotherapy in BCL1 lymphoma in an FcγR-dependent.

Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ) in vivo. Combined loss of MPG and ATM sensitizes pGBM cells to temozolomide (TMZ)

Endogenously produced n-3 PUFAs inhibit endometrial cancer cell growth in vitro and in vivo. Endogenously produced n-3 PUFAs inhibit endometrial cancer.

Immunologic and pharmacokinetic studies.

ESKM is superior to ESK1 in vivo, and is effective against multiple tumor models. ESKM is superior to ESK1 in vivo, and is effective against multiple tumor.

Efficacy of DC therapy is synergistically enhanced by combination therapy with TAM depletion in mesothelioma mouse models. Efficacy of DC therapy is synergistically.

Combination CDN and PD-L1 mAb treatment of established MOC1 tumors produces consistent tumor rejection. Combination CDN and PD-L1 mAb treatment of established.

Activation of Vγ9 T cells by three distinct stimuli is CD277 dependent

Expression of B7-H1, B7-DC, and PD-1 on B cells.

The CD8+ cytotoxic T-cell response in Ron TK−/− hosts in response to tumors is necessary and sufficient to block metastasis. The CD8+ cytotoxic T-cell.

Mice treated with DC therapy and/or M-CSFR inhibition were protected from tumor rechallenge with combination therapy-treated mice displaying superior recall.

C7R enhances adoptive T-cell immunotherapy against metastatic and intracranial malignancies.A and B, 1 × 106 CHLA-255 FFluc cells were injected i.v. into.

Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent regulation of tumor growth. Effect of inhibiting HO-1 on adaptive immune- and cytokine-dependent.

Response of Tet2−/− Flt3ITD leukemia model to 5-Aza therapy.

Anti-CD40 activates TAMs and recruits inflammatory monocytes.

The PI3Kβ inhibitor enhances the antitumor activity of T cell–mediated immunotherapy in mice bearing PTEN loss tumors. The PI3Kβ inhibitor enhances the.

MGA271 exhibits potent in vivo antitumor activity toward tumor cell carcinoma xenografts. MGA271 exhibits potent in vivo antitumor activity toward tumor.

Combination of R848 and anti-CD200R affects activation of tumor-infiltrating myeloid cells. Combination of R848 and anti-CD200R affects activation of tumor-infiltrating.

Effect of MZ treatment on lung colony formation in an experimental metastasis. Effect of MZ treatment on lung colony formation in an experimental metastasis.

Immune checkpoint molecule expression in primary and secondary tumors following radiotherapy. Immune checkpoint molecule expression in primary and secondary.

Constitutive expression of JAK3M511I and HOXA9 leads to development of both AML and T-ALL in vivo. Constitutive expression of JAK3M511I and HOXA9 leads.

Immune response of CEA-transgenic mice transferred with OT-1 splenocytes and immunized with ovalbumin and adjuvant. Immune response of CEA-transgenic mice.

Antibody-mediated blockade of the immune-inhibitory PD-1–PD-L1 signaling pathway prolongs survival in poly(I:C)-treated mice. Antibody-mediated blockade.

Flavopiridol inhibits rhabdoid cell survival and induces cell cycle arrest and apoptosis. Flavopiridol inhibits rhabdoid cell survival and induces cell.

MYC expression is correlated with dasatinib sensitivity in cancer cell lines and in vivo. MYC expression is correlated with dasatinib sensitivity in cancer.

Intratumoral injections of small doses of agonist anti-CD137 mAb to directly act on CD137+ TILs render systemic immunotherapeutic effects that are synergistic.

Induction of PD-1 in B cells by TLR agonists and primary HCC-SN.

Effect of HDC on the ROS production in mouse lungs after melanoma cell inoculation. Effect of HDC on the ROS production in mouse lungs after melanoma cell.

In vivo efficacy of JAK inhibition in transformed Pax5+/− pro-B cells harboring Jak3V670A. In vivo efficacy of JAK inhibition in transformed Pax5+/− pro-B.

ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared with ibrutinib. ARQ 531 improves survival in the Eμ-TCL1 engraftment model compared.

Depletion of CD8+, CD4+, and Ly6G+ cells in subcutaneous TUBO tumor-bearing BALB/c mice treated with KM100 + MTX. Depletions were conducted by intraperitoneal.

Ezh2 inactivation inhibits initiation/progression of CML and establishment of secondary leukemia from existing LICs. A, protocol for induction of Ezh2.

Inhibition of MCL1 reduces AML in an in vivo murine model.

Parthenolide inhibits tumor promotion and increases p21 expression in vivo. Parthenolide inhibits tumor promotion and increases p21 expression in vivo.

Presentation transcript:

TCR stimulation by agonistic mAb in vivo administration inhibits mouse T-ALL development. TCR stimulation by agonistic mAb in vivo administration inhibits mouse T-ALL development. A and B, percentage of TEL-JAK2/TCR-HY leukemic cells in peripheral blood (PB; A) and Kaplan–Meier survival curves (B) of female mice treated daily as indicated (arrows) with hamster anti-CD3 mAb or control IgG. C, percentage of TEL-JAK2 leukemic cells (expressing endogenous TCR) in peripheral blood leukocytes of mice that were treated daily with anti-CD3 or control hamster IgG. D, Kaplan–Meier survival curves of mice injected with either TEL-JAK2 leukemic cells (expressing endogenous TCR), or TEL-JAK2/CD3ε−/− leukemic cells and treated daily with anti-CD3 or control hamster IgG. E, percentage of IKL/L leukemic cells in peripheral blood leukocytes defined as FSChi, Thy1.2+ CD25+ in control IgG or anti-CD3–treated NOD/SCID/γc−/− (NSG) mice at the indicated time point. F, Kaplan–Meier survival curves of NSG mice injected with IKL/L leukemic cells treated with hamster anti-CD3 mAb or control IgG as indicated. Amélie Trinquand et al. Cancer Discov 2016;6:972-985 ©2016 by American Association for Cancer Research